Venetoclax, an FDA-approved BH3-mimetic molecule that binds with high affinity to BCL2, demonstrated impressive initial clinical activity; however, about 50% of high-risk CLL patients relapse after two years of venetoclax monotherapy [5]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.